PROFESSIONAL :

• Caring Cardiology Medical Group, 12/2008 – present
  Laguna Hills, California
• Pacific Cardiovascular Associates, 8/2001 – 12/2008
  Private Practice Interventional Cardiologist
  Director, Peripheral Vascular Intervention
  Co-Director, Nuclear Cardiology Program and Radiation Safety Officer
  Laguna Hills, California
• University of Southern California Keck School of Medicine, 9/1999 – 7/2001
  Assistant Professor, Division of Cardiology
  Interventional Cardiologist
  Director, Peripheral Vascular Intervention
  Assistant Director, Cardiac Catheterization Laboratory
  Los Angeles, California
  

ADMINISTRATIVE POSITIONS :

• Fellowships:

• Residency:

• Medical School:

• Undergraduate:
  

MEDICAL BOARD CERTIFICATIONS :

• Nuclear Cardiology, The Certification Board of Nuclear Cardiology, 2003
• Diplomate in Interventional Cardiology, American Board of Internal Medicine, 1999
• Diplomate in Cardiovascular Disease, American Board of Internal Medicine, 1997 and 2007
• Diplomate in Internal Medicine, American Board of Internal Medicine, 1994
• Diplomate of the National Board of Medical Examiners, 1991
  

• National VHA award for Door to Balloon Time for Primary PCI, 2006
• Alpha Omega Alpha Honor Medical Society, 1991
• Juvenile Diabetes Foundation Fellowship Award, 1988
• Sigma Xi Honor Society, 1987
• Society of Nuclear Medicine Fellowship award, 1985
• National Merit Finalist, 1983
  

PROFESSIONAL SOCIETY MEMBERSHIPS :

• Fellow, The Society for Cardiovascular Angiography and Interventions
• Fellow, American College of Cardiology (ACC)
• Fellow, Society for Vascular Medicine (SVM)
• Member, American Heart Association (AHA)
  

• Animal Research in Cardiology: The Cleveland Clinic Foundation; Cleveland, Ohio, 1995 to 1999; Preceptors: Eric J. Topol, M.D. and A. Michael Lincoff, M.D.
  • The role of integrins αIIbβ3 (glycoprotein IIb/IIIa) and αvβ3 (vitronectin receptor) in the restenosis process in the guinea pig carotid artery injury model; Merck KGaA Research Grant, 1997 and DuPont Merck Pharmaceuticals, 1995
  • The effect of a selective oral αIIbβ3 (glycoprotein IIb/IIIa) inhibitor on intimal hyperplasia in the guinea pig carotid artery injury model of restenosis according to the timing of administration and length of therapy; Searle Pharmaceuticals Research Grant, 1995
  • The effect of a selective αvβ3 (vitronectin receptor) inhibitor on intimal hyperplasia in the rabbit femoral artery injury model of restenosis; IXSYS Research grant, 1996
• Laboratory Research in Diabetes: University of Michigan; Ann Arbor, Michigan
  Summer 1988; Preceptor: Douglas A. Greene, M.D.
• Characterization of myo-inositol depletion in human retinal pigment epithelial cells in vitro as a model for diabetic complications
• Clinical Research in Nuclear Medicine: University of Michigan; Ann Arbor, Michigan, Summer 1985; Preceptor: William H. Beierwaltes, M.D.
  • Evaluation of the prevalence of metastatic disease in patients with pheochromocytomas
• Laboratory Research in Oncology: Providence Hospital; Southfield, Michigan Summer 1984; Preceptor: Yu Min Chen, Ph.D.
  • Optimization of the estrogen and progesterone receptor radioimmunoassays for breast and uterine carcinomas
    

• Executive Program in Practice Management, Cleveland Clinic Foundation, 9/97 – 4/98
• Manuscript reviews for Circulation, Circulation Research, Journal of Cardiovascular Pharmacology, Cardiovascular Drugs and Therapy, and The American Journal of Pathology
• Abstract reviews for the 71st Scientific Sessions of the American Heart Association meeting in November, 1998
  

INVITED LECTURERS :

• 5/12/1999 Hospital Universitario Esperanza, Guatemala City, Guatemala, “Heart Disease and Lipid Management in Women”
• 1/4/2000 University of Southern California Cardiology grand Rounds, Los Angeles, CA, “Renovascular Hypertension”
• 2/9/2000 Midway Hospital Medical Center, Los Angeles, CA, “Percutaneous Coronary Intervention”
• 2/16/2000 Huntington Memorial Hospital, Pasadena, CA, “Renovascular Hypertension”
• 4/13/2000 Garfield Medical Center, Los Angeles, CA, “Percutaneous Coronary Intervention”
• 4/18/2000 San Dimas Community Hospital, San Dimas, CA, “Percutaneous Coronary Intervention”
• 5/1/2000 Keck School of Medicine of the University of Southern California, Los Angeles, CA, “Coronary Artery Disease in Women”
• 5/4/2000 University of Southern California Nephrology Grand Rounds, Los Angeles, CA, “Renovascular Hypertension”
• 6/10/2000 The Society for Vascular Medicine and Biology – 11th Annual Meeting, Toronto, Canada, moderator for “Brachytherapy for Prevention of Restenosis”
• 9/22/2000 Endovascular Therapy for the Year 2000 – The Fourth Annual Max R. Gaspar Vascular Disease Symposium, presented by Division of Vascular Surgery, Keck School of Medicine of the University of Southern California, Glendale, CA, “Carotid Stenting – A Cardiology Perspective”
• 2000-2001 Partners Program, Series of 3 lectures, Los Angeles, CA, “Peripheral Arterial Disease”
• 2/2/2004 City of Irvine Senior Services Outreach Program and The Irvine Regional Hospital, Irvine, CA, “Heart Disease”
• 3/18/2006 Irvine Regional Hospital Horizons in Cardiology 2006, Irvine, CA, “Carotid Intervention: The New Frontier is Here”
• 9/29/2007 The Heart of the Matter presented by Pacific Cardiovascular Associates, Irvine, CA, “Diagnosis and Treatment of Peripheral Vascular Disease”
  

• EPILOG
  The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine 1997; 336: 1689-96.
• EPISTENT
  The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
• RAPPORT
  Brener SJ, Barr LA, Burchenal JEB, Katz S, George bS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-41.
  

PUBLICATIONS :

• Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach H, Selzer RH for the WELL-HEART Research Group. Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART): A Randomized Trial. The New England Journal of Medicine 2003; 349(6): 535-45.
• Rabbani R, Le Breton H, Khurana C, Forudi F, Plow EF, Mousa SA, Lincoff AM. The role of integrins αvβ3 and αIIbβ3 in an experimental arterial injury model (abstract). Poster presentation: American Heart Association meeting; Dallas, TX, 1998, Circulation 1998; 98: I-535.
• Byzova TV, Rabbani R, D’Souza S, Plow EF. Role of integrin αvβ3
  in vascular biology. Thrombosis and Haemostasis 1998; 80; 80: 726-34.
• Le Breton H, Rabbani R, Plow EF, Mousa SA, Lincoff aM, Forudi F, Topol EJ. The role of integrins αIIbβ3 (glycoprotein IIb/IIIa) and αvβ3 (vitronectin receptor) in a guinea pig model of restenosis (abstract). Poster presentation: Restenosis Summit; Cleveland, OH, 1996. Oral presentation: American Heart Association meeting; New Orleans, LA, 1996. Circulation 1996; 94; I-517.
• Del Monte MA, Rabbani R, Diaz TC, Greene DA. Sorbitol, myo-inositol and rod outer segment phagocytosis in cultured human retinal pigment epithelial cells exposed to glucose; in vitro model of myo-inositol depletion hypothesis of diabetic complications. Diabetes 1991; 40: 1335-45.
• Beierwaltes WH, Sisson JC, Shapiro B, Lloyd RV, Dmuchowski C, Rabbani R. Malignant potential of pheochromocytoma: Implications for follow-up (abstract). Journal of Nuclear Medicine 1986; 27: 908.